IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v583y2020i7815d10.1038_s41586-020-2349-y.html
   My bibliography  Save this article

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Author

Listed:
  • Dora Pinto

    (Vir Biotechnology)

  • Young-Jun Park

    (University of Washington)

  • Martina Beltramello

    (Vir Biotechnology)

  • Alexandra C. Walls

    (University of Washington)

  • M. Alejandra Tortorici

    (University of Washington
    Unité de Virologie Structurale)

  • Siro Bianchi

    (Vir Biotechnology)

  • Stefano Jaconi

    (Vir Biotechnology)

  • Katja Culap

    (Vir Biotechnology)

  • Fabrizia Zatta

    (Vir Biotechnology)

  • Anna De Marco

    (Vir Biotechnology)

  • Alessia Peter

    (Vir Biotechnology)

  • Barbara Guarino

    (Vir Biotechnology)

  • Roberto Spreafico

    (Vir Biotechnology)

  • Elisabetta Cameroni

    (Vir Biotechnology)

  • James Brett Case

    (Washington University School of Medicine)

  • Rita E. Chen

    (Washington University School of Medicine
    Washington University School of Medicine)

  • Colin Havenar-Daughton

    (Vir Biotechnology)

  • Gyorgy Snell

    (Vir Biotechnology)

  • Amalio Telenti

    (Vir Biotechnology)

  • Herbert W. Virgin

    (Vir Biotechnology)

  • Antonio Lanzavecchia

    (Vir Biotechnology
    Università della Svizzera Italiana)

  • Michael S. Diamond

    (Washington University School of Medicine
    Washington University School of Medicine
    Washington University School of Medicine)

  • Katja Fink

    (Vir Biotechnology)

  • David Veesler

    (University of Washington)

  • Davide Corti

    (Vir Biotechnology)

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.

Suggested Citation

  • Dora Pinto & Young-Jun Park & Martina Beltramello & Alexandra C. Walls & M. Alejandra Tortorici & Siro Bianchi & Stefano Jaconi & Katja Culap & Fabrizia Zatta & Anna De Marco & Alessia Peter & Barbara, 2020. "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody," Nature, Nature, vol. 583(7815), pages 290-295, July.
  • Handle: RePEc:nat:nature:v:583:y:2020:i:7815:d:10.1038_s41586-020-2349-y
    DOI: 10.1038/s41586-020-2349-y
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-020-2349-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1038/s41586-020-2349-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:583:y:2020:i:7815:d:10.1038_s41586-020-2349-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.